Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2020
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 5,250,000 shares of Common Stock at $4.00 per share.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 787,500 additional shares.
- Underwriter's Warrants: Warrants to purchase 7% of total shares sold (including additional shares) at an exercise price of $4.80 per share. Exercisable after six months for a three-year period.
- Expected Net Proceeds: Approximately $19.3 million (after underwriting discount and estimated expenses).
- Expected Closing Date: On or about March 2, 2020.
Material Changes and Use of Proceeds
This filing represents a material change in the company's capital structure through a new equity offering. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period. The net proceeds are designated for:
- Anticipated Phase 3 clinical trial for ORMD-0801 (Oral Insulin).
- Other clinical trials and research and development activities.
- General corporate purposes.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the capital to advance the Phase 3 clinical trial for its oral insulin candidate.
Risks and Contingencies:
- The closing of the offering is subject to customary conditions and contingencies; failure to satisfy these may prevent the offering from closing.
- Forward-looking statements regarding the closing date and use of proceeds are not guaranteed.
- The company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Confirm the actual closing date of the offering (expected March 2, 2020) and whether the over-allotment option was exercised.
- Verify the final net proceeds received after all expenses and discounts.
- Monitor the progress and results of the Phase 3 clinical trial for ORMD-0801 funded by this offering.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific conditions precedent to closing.